Nautilus Biotechnology, INC

Nautilus Biotechnology, Inc. held its 2026 annual meeting, where stockholders elected Class II directors, ratified the appointment of PricewaterhouseCoopers LLP, and approved executive compensation and the frequency of future advisory votes.

Nautilus Biotechnology reported reduced operating expenses and net loss for Q4 and FY 2025, while launching its Iterative Mapping Early Access Program.

Nautilus Biotechnology, Inc. announced it has regained compliance with Nasdaq's minimum bid price requirement, resolving a previous listing deficiency.

Nautilus Biotechnology reported a reduced net loss and decreased operating expenses in Q3 2025, while making progress towards its late 2026 commercial launch.

Nautilus Biotechnology reports reduced Q2 2025 net loss and operating expenses, alongside significant scientific milestones and new research collaborations.

Nautilus Biotechnology, Inc. announced the results of its 2025 annual meeting of stockholders, including the election of two Class I directors and the ratification of PricewaterhouseCoopers LLP as its independent registered public accounting firm.

Nautilus Biotechnology reported a net loss of $14.5 million for Q2 2026, a slight improvement from the prior year, while also announcing a strategic shift to prioritize proteoform development over its broadscale assay.

Nautilus Biotechnology reports a decrease in operating expenses for Q1 2026, driven by lower R&D and SG&A costs, while cash reserves remain sufficient for at least the next 12 months.

Nautilus Biotechnology, a development-stage proteomics company, reported reduced net losses and operating expenses for Q3 2025, while addressing a Nasdaq minimum bid price compliance issue.

Nautilus Biotechnology reported a reduced net loss in the second quarter of 2025, driven by cost optimization efforts, as it continues to advance its proteomics platform towards a late 2026 commercial launch while addressing a Nasdaq minimum bid price deficiency.

Nautilus Biotechnology reports a net loss for Q1 2025 while continuing to advance the development of its proteomics platform.

Nautilus Biotechnology's Q3 2024 report reveals a net loss of $16.4 million, with ongoing investments in research and development.

Nautilus Biotechnology, a development-stage life sciences company, reported a net loss of $59.0 million for 2025 as it continues to invest heavily in its Nautilus Voyager™ proteomics platform, targeting a phased commercial launch in late 2026.

Nautilus Biotechnology's 2024 10-K filing highlights ongoing development of its proteomics platform and its commercialization strategy.

Nautilus Biotechnology's 2023 annual report highlights its ongoing development of a proteomics platform, strategic partnerships, and a three-phase commercialization plan, while acknowledging significant net losses and the need for future capital.

Entities affiliated with Andreessen Horowitz sold approximately 5 million shares of Nautilus Biotechnology, Inc. on June 2, 2026.

Nautilus Biotechnology's CEO, President, and Secretary, Sujal Patel, acquired 25,000 shares of common stock for approximately $65,237, signaling continued confidence in the company.

Nautilus Biotechnology's CFO and Treasurer, Anna Mowry, was granted 160,000 stock options with an exercise price of $2.32 per share, vesting over time.

Nautilus Biotechnology, Inc. has granted Chief Scientist Parag Mallick 280,000 stock options with a $2.32 exercise price, vesting over four years.

Nautilus Biotechnology's CEO, Sujal Patel, was granted 650,000 stock options with an exercise price of $2.32, vesting over four years.

Nautilus Biotechnology, Inc. granted its Senior VP of Product Development, Sankar Subramanian, 160,000 stock options with an exercise price of $2.32, vesting over several years.

Nautilus Biotechnology, Inc. has issued its definitive proxy statement, announcing its 2026 Annual Meeting of Stockholders to be held virtually on June 17, 2026, detailing proposals for director elections, auditor ratification, and executive compensation.

Nautilus Biotechnology announces its 2025 Annual Meeting of Stockholders to be held virtually on June 20, 2025, outlining key voting items including the election of directors and ratification of the company's accounting firm.

Nautilus Biotechnology is set to hold its annual stockholder meeting on June 20, 2025, to elect directors and ratify the appointment of PricewaterhouseCoopers LLP as its independent accounting firm.

Nautilus Biotechnology has scheduled its 2024 Annual Meeting for June 13, 2024, and is providing proxy materials to stockholders for voting on key proposals.

Nautilus Biotechnology announces its annual meeting of stockholders to be held virtually on June 13, 2024, to elect directors and ratify the appointment of its independent accounting firm.

Several investment funds affiliated with Andreessen Horowitz have reported a reduction in their beneficial ownership of Nautilus Biotechnology, Inc. common stock.

Andreessen Horowitz entities sold 5 million shares of Nautilus Biotechnology in a block trade, reducing their stake.

Sujal Patel, a key insider, increased his beneficial ownership in Nautilus Biotechnology, Inc. to 16.3% through recent option grants and open market purchases.

Parag Mallick, a key insider, has increased his beneficial ownership in Nautilus Biotechnology, Inc. to 17.6% through a recent option grant.

Perceptive Advisors has filed an amended Schedule 13D, disclosing an updated beneficial ownership of 10.1% in Nautilus Biotechnology, Inc. and the departure of Michael Altman from the company's Board of Directors.

Parag Mallick, a key insider, has increased his beneficial ownership in Nautilus Biotechnology, Inc. to 17.4% of outstanding common stock, primarily through direct holdings and a recent option grant.